Bleeding prediction by rotational thromboelastometry in chronic hemodialysis patients with non-valvular atrial fibrillation on apixaban

Figure 1 Correlations of apixaban level and Platelet Function Analyzer-200 with EXTEM clotting time. A: The difference in apixaban levels (peak minus trough) and the difference in rotational thromboelastometry with EXTEM reagent clotting time values (post-administration minus pre-administration); B: Platelet Function Analyzer-200 assay (closure time) and the difference in rotational thromboelastometry with EXTEM reagent clotting time values (post-administration minus pre-administration) stratified by groups with and without bleeding events. Blue circles and trendlines indicate patients without bleeding events, while red circles and trendlines lines represent patients with bleeding events. CT: Clotting time.

Figure 2 Receiver operating characteristic curve analysis of rotational thromboelastometry with EXTEM reagent clotting time-post drug administration for the prediction of bleeding risk in hemodialysis patients on apixaban for non-valvular atrial fibrillation. AUC: Area under the curve.

Figure 3 Apixaban levels and clotting time-post evaluation across the four drug dosage groups. A: Distribution of apixaban plasma concentrations across prescribed dose groups, displayed as box-and-whisker plots. Boxes represent the interquartile range with the median shown as a horizontal line; whiskers indicate values within 1.5 × interquartile range, and points beyond are outliers; B: Post-drug clotting time (clotting time-post) values across apixaban dose groups, presented as box-and-whisker plots. Boxes represent the interquartile range with the median shown as a horizontal line, whiskers indicate values within 1.5 × interquartile range, and points beyond are outliers; C: Post-treatment clotting time (clotting time-post) mean values across apixaban dose groups, further stratified by the presence or absence of bleeding events. CT: Clotting time.